Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

DDY391

Other · developed by Novartis Pharmaceuticals

Phase 2 Most advanced trial
NVS Developer
1 Registered trials

What is DDY391?

DDY391 is a drug studied in rheumatoid arthritis. The available source text does not describe its molecular class, target or mechanism of action.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Immunology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07951086 Phase 2 Rheumatoid Arthritis Not yet recruiting NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rheumatoid Arthritis

More from Novartis Pharmaceuticals

Follow NVS, the company behind DDY391

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.